NCT06304818View on ClinicalTrials.gov

Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB14 in Adult Patients With Advanced Malignant Solid Tumours.

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

515

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

December 30, 2027

Study Completion Date

December 30, 2028

Conditions
Advanced Malignant Solid Tumours
Interventions
DRUG

SCTB14

SCTB14,IV

All Listed Sponsors
lead

Sinocelltech Ltd.

INDUSTRY